Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Akero Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Akero Therapeutics, Inc.

AKRO

Akero Therapeutics, Inc.

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is an engineered analog of the hormone FGF21 designed to reverse liver fibrosis and cirrhosis while improving metabolic health. Akero’s business model centers on advancing EFX through clinical trials and eventual commercialization targeting patients with advanced liver disease and related metabolic conditions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Akero Therapeutics, Inc.

1
1
Akero Therapeutics, Inc. Akero Therapeutics Reports $81.6 Million Net Loss in Q3 2025, Announces Merger with Novo

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Akero Therapeutics, Inc. Akero Therapeutics Reports $70.5 Million Net Loss in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Akero Therapeutics, Inc. Akero Therapeutics Reports $70.7 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Akero Therapeutics, Inc. Akero Therapeutics Reports $252M Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
Akero Therapeutics, Inc. Akero Therapeutics Reports 88% Year-Over-Year Net Loss Increase, Raises $344.8 Million in Follow-On Public Offering

Via official filing (AI summary) | over 1 year ago | 0 comments